about
Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failureInduction of T-cell tolerance in a patient with idiopathic thrombocytopenic purpura by single injection of humanized monoclonal antibody to CD40 ligand.Novel treatments for immune thrombocytopenia.Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa.Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis.Therapy of systemic lupus erythematosus: new agents and new evidence.Early growth response-1 is required for CD154 transcription.CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation.Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis.Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.The dinucleotide repeat polymorphism in the 3'UTR of the CD154 gene has a functional role on protein expression and is associated with systemic lupus erythematosus.Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.Links between type I interferons and the genetic basis of disease in mouse lupus.Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.Increased CD40 Expression Enhances Early STING-Mediated Type I Interferon Response and Host Survival in a Rodent Malaria Model.Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154.B lymphocytes as therapeutic targets in systemic lupus erythematosus.The hyper IgM syndromes.Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men.Recent advances and current state of immunotherapy in systemic lupus erythematosus.Induction of immunologic tolerance for transplantation.Early reduction of the over-expression of CD40L, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: possible implications for lymphocyte traffic and functional recovery.Autoreactive murine Th1 and Th2 cells kill syngeneic macrophages and induce autoantibodies.Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome.Therapeutic effects of anti-CD154 antibody in cynomolgus monkeys with advanced rheumatoid arthritis.Estrogen does not regulate CD154 mRNA stability in systemic lupus erythematosus T cells.A T-cell-specific CD154 transcriptional enhancer located just upstream of the promoter.Signalling defects and cellular interactions (2).Platelet CD40 contributes to enhanced monocyte chemoattractant protein 1 levels in patients with resistant hypertension.Production of pathogenic antibodies: cognate interactions between autoimmune T and B cells.Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
P2860
Q28166019-F80DDD29-FF70-4EAB-9A76-4702F81D9D24Q33357238-E8CB89A2-CD44-46C0-8F8F-AAE14EBBE1B7Q33414132-A6034996-A5EE-40C5-B0D1-90FD12DF00E8Q33712943-F61C0C86-3E55-43A5-B494-9166D26626B4Q34063451-F15DABE8-DCE6-498C-B56F-A27086C4FC3DQ34074960-2C2250F8-22C0-427A-A6DB-4A5D164C80B8Q34507144-3AF629F6-554F-419B-8319-AD5C952E3757Q35147016-3753231A-2C55-493E-B3A4-F6E6E5AABA77Q35549148-BF08797B-D01A-4913-9175-DBC0F40FA8FBQ35552189-AF217F7C-F6A9-4B6E-8F36-47C0232D45C1Q35553871-0AF847BC-774E-4785-89EA-4B5A95D25101Q35596004-A398AF8C-C188-43CC-9659-D72BDF69FC91Q35675523-FC37B383-6741-4D40-8073-098895DB9125Q35760171-2F2B6394-2D12-4B9C-A735-DA259B169158Q35824531-3ED984F7-C64D-46E1-9D01-0A8D6AFC4E38Q36157771-7FD902AE-E24F-49F1-BB2D-DE2FC72BBB84Q36417432-0BE3BAC4-F9ED-432A-B16F-66F91DB955C4Q36653646-4E1A2713-9C9E-4644-BDAC-1C17B596BEFEQ38116775-D75902D5-74DC-4C82-B9A5-D2808951F610Q38704093-C28A86E0-030B-455B-BF8F-863FA9E868F3Q38794663-C72A06D4-75C6-45F6-95AC-293401EE0F61Q40827011-79F23374-28EB-4F0A-B1AE-58977A8A1BAFQ42472466-DD1D766A-2AF8-4BE6-B453-77F61512401AQ43725027-9B39F9B0-C5E3-4052-921C-D3145895092BQ45874408-56EB8A0F-D5C2-4E72-95D6-A1AB36E81CD0Q49389507-D8723655-1A79-4C17-B1D1-D6CAEDC44D32Q51771134-A7D158D8-605C-4EE6-8799-5580BCCCF3E6Q53458849-EE9F21FD-8B12-414A-836C-E7C9F5DE865EQ53488674-DA5303BD-ED95-4712-9588-A5A02BB3F9B5Q53704529-A2AF8CDE-FF8A-4A06-91B0-302DEEFD4384Q53939339-6191A5A9-B850-4760-9FBD-353F22C19C15Q56904375-6EA7F1DB-0F33-43DB-96E0-5DDCD7766D3E
P2860
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
CD40-CD40 ligand interaction in autoimmune disease.
@en
type
label
CD40-CD40 ligand interaction in autoimmune disease.
@en
prefLabel
CD40-CD40 ligand interaction in autoimmune disease.
@en
P2860
P356
P1476
CD40-CD40 ligand interaction in autoimmune disease.
@en
P2093
P2860
P304
P356
10.1002/ART.1780401002
P577
1997-10-01T00:00:00Z